Publications by authors named "Naoto Kunimura"
Article Synopsis
- Triple-negative breast cancer (TNBC) is challenging to treat, with cancer stem cells (CSCs) contributing to its recurrence and spread.
- Researchers developed a new adenoviral vector (Ad-CD44-N-HIF-3α4) that harnesses a synthetic Notch receptor to target CSCs by using CD44 as a decoy, effectively disrupting cancer cell signals.
- In mouse studies with a highly invasive TNBC cell line, the injection of this vector showed promising antitumor effects, suggesting it could be a potential treatment for TNBC patients.
In this study we undertook a novel combination therapy using rAd-p53 in situ gene therapy and immunotherapy with immune checkpoint inhibitor (ICI) anti-PD-1 antibody for urogenital cancers. Three mouse syngeneic tumor cell lines, TRAMP-C2 (prostate cancer derived from C57BL/6 mice), MBT-2 (bladder cancer derived from C3H mice) and Renca (kidney cancer derived from BALB/c mice) were used in this study. The highest coxsackie and adenovirus receptor (CAR) mRNA expression was observed in TRAMP-C2 cells, followed by Renca and then MBT-2 cells.
View Article and Find Full Text PDFProstate cancer is one of the most common cancers in men. The overactivation of IL-6/JAK/STAT3 signaling and silencing of SOCS3 are frequently observed in prostate cancer. In the present study we undertook to develop Ad-SOCS3 gene therapy for the treatment of prostate cancer and also investigated whether Ad-SOCS3 increased sensitivity to NK cells.
View Article and Find Full Text PDF